- Home
- TORO vs ERNA Comparison
TORO vs ERNA Comparison
Compare TORO & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- ERNA
- Stock Information
- Founded
- TORO 2022
- ERNA 2018
- Country
- TORO Cyprus
- ERNA United States
- Employees
- TORO N/A
- ERNA N/A
- Industry
- TORO Marine Transportation
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- ERNA Health Care
- Exchange
- TORO Nasdaq
- ERNA Nasdaq
- Market Cap
- TORO 62.4M
- ERNA 56.4M
- IPO Year
- TORO N/A
- ERNA N/A
- Fundamental
- Price
- TORO $2.67
- ERNA $0.60
- Analyst Decision
- TORO
- ERNA
- Analyst Count
- TORO 0
- ERNA 0
- Target Price
- TORO N/A
- ERNA N/A
- AVG Volume (30 Days)
- TORO 42.7K
- ERNA 134.6K
- Earning Date
- TORO 11-12-2024
- ERNA 11-12-2024
- Dividend Yield
- TORO N/A
- ERNA N/A
- EPS Growth
- TORO N/A
- ERNA N/A
- EPS
- TORO 0.99
- ERNA N/A
- Revenue
- TORO $80,626,531.00
- ERNA $598,000.00
- Revenue This Year
- TORO N/A
- ERNA N/A
- Revenue Next Year
- TORO N/A
- ERNA N/A
- P/E Ratio
- TORO $0.97
- ERNA N/A
- Revenue Growth
- TORO N/A
- ERNA 1072.55
- 52 Week Low
- TORO $2.50
- ERNA $0.52
- 52 Week High
- TORO $6.45
- ERNA $2.63
- Technical
- Relative Strength Index (RSI)
- TORO 33.33
- ERNA 28.86
- Support Level
- TORO $2.50
- ERNA $0.52
- Resistance Level
- TORO $2.79
- ERNA $1.20
- Average True Range (ATR)
- TORO 0.16
- ERNA 0.11
- MACD
- TORO -0.02
- ERNA -0.05
- Stochastic Oscillator
- TORO 18.20
- ERNA 11.76
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About ERNA Eterna Therapeutics Inc.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.